← All trials
NCT06133686
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Apr 1, 2027
- First posted
- Nov 15, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical Research Council-UVRI Uganda Research Unit on AIDSLead sponsor
- University of LondonCollaborator
- University of LondonCollaborator
- University of LondonCollaborator
- University of LondonStudy chair
- Desmond Tutu HIV FoundationCollaborator
- Medical Research Council-UVRI Uganda Research Unit on AIDSOverall official - principal investigator
- Government of UgandaCollaborator
- Assistance Publique - Hôpitaux de ParisCollaborator
- Wits Health Consortium (Pty) LtdCollaborator
- Africa Health Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.